Cowen & Co. analyst Yaron Werber maintained a Buy rating on Exelixis (EXEL) yesterday and set a price target of $25. The company’s shares closed yesterday at $19.34.
According to TipRanks.com, Werber is a 5-star analyst with an average return of 15.1% and a 64.8% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Unum Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Exelixis with a $31.50 average price target, a 62.9% upside from current levels. In a report issued on April 24, Oppenheimer also assigned a Buy rating to the stock with a $28 price target.
See today’s analyst top recommended stocks >>
Exelixis’ market cap is currently $5.9B and has a P/E ratio of 8.76. The company has a Price to Book ratio of 4.50.
Based on the recent corporate insider activity of 92 insiders, corporate insider sentiment is negative on the stock. Most recently, in February 2019, Stelios Papadopoulos, a Director at EXEL sold 26,250 shares for a total of $557,813.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic.
